Drug profile · INN
zidovudine
RETROVIR
zidovudine (RETROVIR) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with ViiV Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — zidovudine
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 20
- Programs
- 8
- Data quality
- 0.89
Quick answer
zidovudine (RETROVIR) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with ViiV Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12404505
Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
granted -
US 12280063
Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease
granted -
US 11814641
Retroviral and lentiviral vectors
granted -
US 11744831
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
granted -
US 11591613
Retroviral and lentiviral vectors
granted -
US 11135283
Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
granted -
US 11065254
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
granted -
US 10954530
Retroviral and lentiviral vectors
granted -
US 10653782
Retroviral particles expressing Sirt1 embedded within PPCN
granted -
US 10584356
Multigenome retroviral vector preparations and methods and systems for producing and using same
granted -
US 10525123
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
granted -
US 10307477
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
granted -
US 10179919
Multigenome retroviral vector preparations and methods and systems for producing and using same
granted -
US 9878002
Compositions and methods involving endogenous retrovirus proteins
granted -
US 9677143
Compositions and methods for the identification of inhibitors of retroviral infection
granted -
US 9249473
Compositions and methods for the identification of inhibitors of retroviral infection
granted -
US 9163248
Targeting pseudotyped retroviral vectors
granted -
US 8993768
Tropolone compounds for treating or preventing retroviral infection
granted -
US 8920812
Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
granted -
US 8680065
Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use
granted
Frequently asked questions
What is zidovudine?
zidovudine (RETROVIR) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with ViiV Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for zidovudine?
RETROVIR is a marketed brand name for zidovudine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zidovudine?
zidovudine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.